Metastatic melanoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A melanoma that has spread from its primary site to another anatomic site. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Metastatic melanoma
- Therapeutic area
- Oncology
- metastatic melanoma
- metastatic malignant melanoma
- Disease mechanisms
- Developmental
Sources for recorded values
- All therapeutic areas
- Oncology
Sources for recorded values
- Severity
- Terminal
- MONDO ID
- MONDO:0005191
- Parent condition
- MONDO:0005105
Related records
Broader conditions (11)
- Cancer or benign tumor
- Disease
- Disease by developmental or physiological process
- Disease by etiologic mechanism
- Disorder of development or morphogenesis
- Human disease
- Melanocytic neoplasm
- Melanoma
- Neoplasm
- Neoplastic disease or syndrome
- Neurocristopathy
Narrower conditions (1)
- Ovarian melanoma
Trials (377)
- 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
- 7T MRI Scan for the Early Detection of Melanoma Brain Metastases
- A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab
- A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma
- A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma
- A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
- A Novel Treatment for Metastatic Melanoma
- A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
- A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
- A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
- A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
- A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma
- A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma
- A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
- A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
- A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
- A Phase I/II Study of Dasatinib and Dacarbazine
- A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma
- A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes
- A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients
Approved drugs (13)
- Aldesleukin
- Binimetinib
- Cobimetinib fumarate
- Dabrafenib mesylate
- Dacarbazine
- Encorafenib
- Ipilimumab
- Lifileucel
- Nivolumab
- Peginterferon alfa-2B
- Pembrolizumab
- Trametinib dimethyl sulfoxide
- Vemurafenib
Drugs in development (145)
- Acetazolamide Phase 1
- Aflibercept Phase 3
- Arsenic trioxide Phase 1
- Atezolizumab Phase 3
- Autogene cevumeran Phase 2
- Azacitidine Phase 2
- Balstilimab Phase 3
- Bavunalimab Phase 1
- Belapectin Phase 1
- Bempegaldesleukin Phase 3
- Bevacizumab Phase 2
- Bupropion Phase 1
- Cabozantinib Phase 2
- Caffeine Phase 1
- Calcitriol Phase 1
- Camrelizumab Phase 3
- Capecitabine Phase 1
- Carboplatin Phase 3
- CD24FC Phase 1
- CDX-1140 Phase 1
Other linked drugs (2)
- Interferon alfa
- Melphalan